Ivermectin and Mebendazole in Cancer Patients

https://zenodo.org/records/19455636

The Clinical Benefit Ratio

Complete Response + Partial Response + Stable Disease / Total Patients

(CBR) was 84.4%

Overall, it is estimated that annual costs of standard chemotherapies average $111,000 per year.

Background: Drug repurposing offers a pathway to identify accessible, low-toxicity cancer therapies. 

Ivermectin and mebendazole have demonstrated multi-target anti-cancer activity. 

This paper evaluates real-world patient-reported outcomes, safety, and adherence in a cohort of cancer patients utilizing this combination protocol.

Methods: 

Prospective observational cohort of 197 cancer patients,

who were prescribed ivermectin and mebendazole off-label through telemedicine (platform by licensed U.S. healthcare providers)

Participants received compounded oral capsules containing 25 mg ivermectin and 250 mg mebendazole. 

Data were collected via voluntary, standardized digital surveys at baseline and at approximately 6-month follow-up. 

Of the initial cohort (N = 197), baseline characteristics, including cancer type and disease status, were assessed. 

A total of 122 participants completed the follow-up survey (61.9% response rate)

Results: 

Mean age of 67 years, (52.3% male, 47.7% female). 

Cancer types included
Prostate  27.9%
Breast  18.3%
Lung  8.6% 
Colon  5.1%
Urologic  4.6%
Pancreatic  3.0%
Liver   2.5%
Gynaecologic 2.5%
Hematologic  2.5% 
Median duration since initial diagnosis, 1.2 years 

37.1% experiencing active disease progression. 

6-month follow-up

Medication adherence, 86.9%

Full initial 90-capsule ivermectin-mebendazole prescription.

The Clinical Benefit Ratio

Complete Response + Partial Response + Stable Disease / Total Patients

(CBR) was 84.4%

Notably, 48.4% of cohort, strongest positive outcomes:

Regression, 15.6%

No current evidence of disease (NED), 32.8%